Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Phase III CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

Nov. 10, 2020

Phase III trial of Nefecon in primary IgAN meets key endpoints

Nov. 9, 2020

CaMK4 as potential target to slow cyst growth in PKD

Nov. 9, 2020

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Nov. 6, 2020

Synlogic advances SYNB-8802 into phase I study for treatment of enteric hyperoxaluria

Nov. 5, 2020

Phase III results for molidustat in patients with renal anemia undergoing dialysis

Nov. 4, 2020

dEF-3122 improves inflammation and fibrosis in liver and kidneys of NASH mice

Nov. 3, 2020

First-in-class LDHA inhibitor CHK-336 for treating primary hyperoxaluria

Nov. 3, 2020

Dimerix announces positive data from phase II ACTION trials of DMX-200 in kidney disease

Oct. 28, 2020

J2H Biotech, Ahn-Gook Pharmaceutical describe new mirabegron prodrugs

Oct. 28, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026